Second, individuals who have previously received limited BRCA1 and BRCA2 gene testing may still harbor a genetic risk of breast and/or ovarian cancer and should be considered for multi-gene panel testing including large rearrangement testing. This evidence concerns the gene BRCA1 and ovarian cancer.